Evidence map›Paper›PMID 34925972›Full record

ReviewCureus2021

Prevalence of Fabry Disease in Patients With Cryptogenic Strokes: A Systematic Review.

Juan Fernando Ortiz, Jashank Parwani, Paul W Millhouse, Ahmed Eissa-Garcés, Gashaw Hassen, Victor D Cuenca, Ivan Mateo Alzamora, Mahika Khurana, Domenica Herrera-Bucheli, Abbas Altamimi and 2 more

Open access · diamondAbstract readReview
In one paragraph

Review in Cureus, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 8 institutions in 5 countries.

Juan Fernando OrtizNeurology, Larkin Community Hospital, Miami, USA.
Jashank ParwaniNeurology, Lokmanya Tilak Municipal Medical College, Mumbai, IND.
Paul W MillhouseGeneral Practice, Drexel University College of Medicine, Philadelphia, USA.
Ahmed Eissa-GarcésNeurology, Universidad San Francisco de Quito, Quito, ECU.
Gashaw HassenMedicine and Surgery, University of Parma, Parma, ITA.
Victor D CuencaMedicine, Universidad San Francisco de Quito, Quito, ECU.
Ivan Mateo AlzamoraNeurology, Universidad San Francisco de Quito, Quito, ECU.
Mahika KhuranaPublic Health, University of California Berkeley, Berkeley, USA.
Domenica Herrera-BucheliMedicine, Universidad Internacional del Ecuador, Quito, ECU.
Abbas AltamimiEmergency Medicine, Amiri Hospital, Kuwait City, KWT.
Adam AtootInternal Medicine, Palisades Medical Center, North Bergen, USA.
Wilson CuevaNeurology, Larkin Community Hospital, Miami, USA.
Larkin Community Hospital · USUniversidad San Francisco de Quito · ECAmiri Hospital · KWBerkeley Public Health Division · USDrexel University · USLokmanya Tilak Municipal General Hospital and Lokmanya Tilak Municipal Medical College · INMercy Medical Center · USUniversidad Internacional del Ecuador · EC

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Fabry disease (FD) is an X-linked disorder involving multiple organs. Stroke is a serious and frequent complication of FD. Cryptogenic stroke is a common presentation of FD, especially in the young population. The etiology of cryptogenic stroke is highly variable and difficult to assess, frequently leaving patients without a primary diagnosis. We conducted a systematic review to investigate the pooled prevalence of FD among patients with cryptogenic stroke, or patients with FD in whom a stroke was the presenting condition. English-language studies involving humans published in the last 20 years were included in this systematic review. FD was more common in male patients and tended to present at an earlier age. The frequency of hemorrhagic and ischemic strokes in this population was similar to that in the general population. There was a high rate of stroke recurrence in the study sample, even among patients undergoing enzyme replacement therapy. We conclude that screening for FD in patients with cryptogenic stroke is low yield and not cost-effective. However, it may be worthwhile to screen for FD among patients with recurrent strokes.

Indexed as

alpha-galactosidasecryptogenic strokefabry diseaseischemic strokestroke

Identifiers

PMID34925972
PMCPMC8654093
OpenAlexW3212924158

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.